Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer that is HR-positive and HER2-negative, confirmed by a biopsy.
- Your cancer has gotten worse during or after your last treatment.
- You have not received chemotherapy for advanced cancer, but you may have had it before surgery if it was more than 6 months ago.
- Your doctor decides hormone therapy is no longer helping and you are ready for first chemotherapy.
- You can provide a tumor tissue sample from a recent biopsy or from when your cancer spread.
- You have at least one tumor that can be measured on scans.
- You are in good physical health (able to do daily activities) and have a life expectancy of at least 12 weeks.
- You have recovered from side effects of previous treatments.
- You agree to use effective birth control during the study and for 6 months after last dose.
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.